Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Belantamab mafodotin[1] Belantamab mafodotin (Belantamab mafodotin)[1] Belantamab mafodotin (Belantamab mafodotin, Belantamab mafodotin, Belantamab mafodotin-blmf) 💬 [10] TNFRSF17,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB 💬 		[13] Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Motor proteins, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬[1] 28 💬
2Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks AS determined BY part 1 recommended dosages[1] Belantamab mafodotin (Belantamab mafodotin)[1] Belantamab mafodotin (Belantamab mafodotin, Belantamab mafodotin, Belantamab mafodotin-blmf) 💬 [10] TNFRSF17,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB,
TUBB 💬 		[13] Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Motor proteins, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬[1] 28 💬